VistaSeq℠ Endocrine Cancer Panel

CPT: 81437; 81438
Print Share

Test Details


  • Familial Cancer testing
  • Hereditary Cancer testing
  • Inherited Cancer testing


This assay is intended for patients with a family history consistent with an inherited cancer syndrome.


This assay is not designed to detect deep intronic variants, balanced translocations, large inversions, mosaicism or complex genomic rearrangements. Homopolymer regions and rare polymorphisms under primer sites can affect the performance of the assay. The presence of pseudogenes can interfere with the ability to detect variants in certain genes. This assay is not intended for use in patients who have received allogeneic bone marrow transplants, as it may not reflect the germline genetic status of these patients.

This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).


The entire coding region of a panel of genes related to hereditary cancer is examined by next generation sequencing analysis. Additionally, portions of the flanking noncoding regions are also examined. Comprehensive deletion/ duplication testing is performed using microarray CGH for 13 genes. Genes tested in this panel include CDC73, MAX, MEN1, NF1, PRKAR1A, PTEN, RET, SDHB, SDHC, SDHD, TMEM127, TP53 and VHL. Clinically significant findings are confirmed by Sanger sequencing or qPCR. Results are reported using ACMG guidelines and nomenclature recommended by the Human Genome Variation Society (HGVS).

Specimen Requirements


Whole blood


10 mL

Minimum Volume

7 mL


Lavender-top (EDTA) tube or yellow-top (ACD) tube


Blood is collected by routine phlebotomy.

Storage Instructions

Room temperature

Causes for Rejection

Frozen or hemolyzed specimen; quantity not sufficient for analysis

Clinical Information

Special Instructions

A Hereditary Cancer Clinical Questionnaire should be submitted with all specimens. Contact CMBP genetic services at 800-345-4363 to coordinate testing.


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
481374 VistaSeq Endocrine Cancer 481375 Specimen Type 31208-2
481374 VistaSeq Endocrine Cancer 481376 Preauthorization N/A
481374 VistaSeq Endocrine Cancer 481377 Result Summary 51968-6
481374 VistaSeq Endocrine Cancer 481378 Result and Interpretation 69548-6
481374 VistaSeq Endocrine Cancer 481379 Recommendations 47042-7
481374 VistaSeq Endocrine Cancer 481380 Additional Information 77202-0
481374 VistaSeq Endocrine Cancer 481381 Methodology and Limitations 49549-9
481374 VistaSeq Endocrine Cancer 481382 References 75608-0
481374 VistaSeq Endocrine Cancer 481383 Director Review 72486-4
481374 VistaSeq Endocrine Cancer 481384 PDF 51969-4

For Providers

Please login to order a test.


© 2018  Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2018, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at